Baxter to end Alzheimer's trial of Gammagard

05/8/2013 | Yahoo

Baxter International said it is stopping Phase III Alzheimer's disease trials of Gammagard after the intravenous immunoglobulin failed to enhance mental decline and functional ability in patients. Gammagard, also known as intravenous immunoglobulin, is the only Alzheimer's treatment currently in Phase III development. The firm said it will reevaluate its Alzheimer's program and make a decision after analyzing the trial's full results.

View Full Article in:

Yahoo

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA